

REMARKS/ARGUMENTS

The Claims in the case are 1-5, 12, and 16. Claims 9-11 and 13-14 were cancelled in the preliminary amendment filed June 15, 2006. Claims 6-8, 15 and 17-18 were cancelled in the previous paper filed May 21, 2008. A response to an earlier restriction requirement was filed December 22, 2008.

The Examiner has made a third restriction requirement listing 10 groups. Applicants elect Group IX for examination, drawn to compounds wherein

$$a^1 - a^2 = a^3 - a^4 \text{ is } N\text{-CH=CH-CH} \quad \text{and}$$


Z is NH:


 X^1 is NR^{11} ;

X² is O or O-C₁₋₂ alkyl;

and Y is C₃₋₉ alkyl or C₃₋₉ alkenyl.

For search purposes, Applicants elect as species, the compound 1 having the name of 7*H*,19*H*-4,6-ethanediylidenepyrimido[4,5-*b*][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-,



The structure of this compound is , which is the compound prepared in Example B1 at page 41 of the Specification. The elected compound falls within Group IX. The claims remaining in the application: 1-5, 12, and 16, read on the elected group.

Examination on the merits is respectfully requested.

Respectfully submitted,

/Hesna J. Pfeiffer/

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
Phone: (732) 524-2830
Dated: June 12, 2009

By: Hesna J. Pfeiffer, Reg. 22,640